BACKGROUND AND OBJECTIVES: Clinical trials assessing effects of larger cumulative iron exposure with outcomes are lacking, and observational studies have been limited by assessment of short-term exposure only and/or failure to assess cause-specific mortality. The associations between short- and long-term iron exposure on all-cause and cause-specific mortality were examined. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: The study included 14,078 United States patients on dialysis initiating dialysis between 2003 and 2008. Intravenous iron dose accumulations over 1-, 3-, and 6-month rolling windows were related to all-cause, cardiovascular, and infection-related mortality in Cox proportional hazards models that used marginal structural modeling to control for time-dependent confounding. RESULTS: Patients in the 1-month model cohort (n=14,078) were followed a median of 19 months, during which there were 27.6% all-cause deaths, 13.5% cardiovascular deaths, and 3% infection-related deaths. A reduced risk of all-cause mortality with receipt of >150-350 (hazard ratio, 0.78; 95% confidence interval, 0.64 to 0.95) or >350 mg (hazard ratio, 0.79; 95% confidence interval, 0.62 to 0.99) intravenous iron compared with >0-150 mg over 1 month was observed. There was no relation of 1-month intravenous iron dose with cardiovascular or infection-related mortality and no relation of 3- or 6-month cumulative intravenous iron dose with all-cause or cardiovascular mortality. There was a nonstatistically significant increase in infection-related mortality with receipt of >1050 mg intravenous iron in 3 months (hazard ratio, 1.69; 95% confidence interval, 0.87 to 3.28) and >2100 mg in 6 months (hazard ratio, 1.59; 95% confidence interval, 0.73 to 3.46). CONCLUSIONS: Among patients on incident dialysis, receipt of ≤ 1050 mg intravenous iron in 3 months or 2100 mg in 6 months was not associated with all-cause, cardiovascular, or infection-related mortality. However, nonstatistically significant findings suggested the possibility of infection-related mortality with receipt of >1050 mg in 3 months or >2100 mg in 6 months. Randomized clinical trials are needed to assess the safety of exposure to greater cumulative intravenous iron doses.
BACKGROUND AND OBJECTIVES: Clinical trials assessing effects of larger cumulative iron exposure with outcomes are lacking, and observational studies have been limited by assessment of short-term exposure only and/or failure to assess cause-specific mortality. The associations between short- and long-term iron exposure on all-cause and cause-specific mortality were examined. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: The study included 14,078 United States patients on dialysis initiating dialysis between 2003 and 2008. Intravenous iron dose accumulations over 1-, 3-, and 6-month rolling windows were related to all-cause, cardiovascular, and infection-related mortality in Cox proportional hazards models that used marginal structural modeling to control for time-dependent confounding. RESULTS:Patients in the 1-month model cohort (n=14,078) were followed a median of 19 months, during which there were 27.6% all-cause deaths, 13.5% cardiovascular deaths, and 3% infection-related deaths. A reduced risk of all-cause mortality with receipt of >150-350 (hazard ratio, 0.78; 95% confidence interval, 0.64 to 0.95) or >350 mg (hazard ratio, 0.79; 95% confidence interval, 0.62 to 0.99) intravenous iron compared with >0-150 mg over 1 month was observed. There was no relation of 1-month intravenous iron dose with cardiovascular or infection-related mortality and no relation of 3- or 6-month cumulative intravenous iron dose with all-cause or cardiovascular mortality. There was a nonstatistically significant increase in infection-related mortality with receipt of >1050 mg intravenous iron in 3 months (hazard ratio, 1.69; 95% confidence interval, 0.87 to 3.28) and >2100 mg in 6 months (hazard ratio, 1.59; 95% confidence interval, 0.73 to 3.46). CONCLUSIONS: Among patients on incident dialysis, receipt of ≤ 1050 mg intravenous iron in 3 months or 2100 mg in 6 months was not associated with all-cause, cardiovascular, or infection-related mortality. However, nonstatistically significant findings suggested the possibility of infection-related mortality with receipt of >1050 mg in 3 months or >2100 mg in 6 months. Randomized clinical trials are needed to assess the safety of exposure to greater cumulative intravenous iron doses.
Authors: Kamyar Kalantar-Zadeh; Deborah L Regidor; Charles J McAllister; Beckie Michael; David G Warnock Journal: J Am Soc Nephrol Date: 2005-07-20 Impact factor: 10.121
Authors: Daniel W Coyne; Toros Kapoian; Wadi Suki; Ajay K Singh; John E Moran; Naomi V Dahl; Adel R Rizkala Journal: J Am Soc Nephrol Date: 2007-01-31 Impact factor: 10.121
Authors: Elani Streja; Csaba P Kovesdy; Sander Greenland; Joel D Kopple; Charles J McAllister; Allen R Nissenson; Kamyar Kalantar-Zadeh Journal: Am J Kidney Dis Date: 2008-08-29 Impact factor: 8.860
Authors: Stefan D Anker; Josep Comin Colet; Gerasimos Filippatos; Ronnie Willenheimer; Kenneth Dickstein; Helmut Drexler; Thomas F Lüscher; Boris Bart; Waldemar Banasiak; Joanna Niegowska; Bridget-Anne Kirwan; Claudio Mori; Barbara von Eisenhart Rothe; Stuart J Pocock; Philip A Poole-Wilson; Piotr Ponikowski Journal: N Engl J Med Date: 2009-11-17 Impact factor: 91.245
Authors: Toros Kapoian; Neeta B O'Mara; Ajay K Singh; John Moran; Adel R Rizkala; Robert Geronemus; Robert C Kopelman; Naomi V Dahl; Daniel W Coyne Journal: J Am Soc Nephrol Date: 2008-01-23 Impact factor: 10.121
Authors: Lynda A Szczech; Huiman X Barnhart; Jula K Inrig; Donal N Reddan; Shelly Sapp; Robert M Califf; Uptal D Patel; Ajay K Singh Journal: Kidney Int Date: 2008-07-02 Impact factor: 10.612
Authors: Ingrid Hougen; David Collister; Mathieu Bourrier; Thomas Ferguson; Laura Hochheim; Paul Komenda; Claudio Rigatto; Navdeep Tangri Journal: Clin J Am Soc Nephrol Date: 2018-02-20 Impact factor: 8.237
Authors: Xiaojuan Li; Stephen R Cole; Abhijit V Kshirsagar; Jason P Fine; Til Stürmer; M Alan Brookhart Journal: Clin J Am Soc Nephrol Date: 2019-04-15 Impact factor: 8.237
Authors: Julie H Ishida; Ben J Marafino; Charles E McCulloch; Lorien S Dalrymple; R Adams Dudley; Barbara A Grimes; Kirsten L Johansen Journal: Clin J Am Soc Nephrol Date: 2015-09-28 Impact factor: 8.237